NINGBO INNO PHARMCHEM CO.,LTD. is committed to providing comprehensive information on key pharmaceutical compounds. This article focuses on Tasimelteon, offering an overview relevant to medical professionals involved in the treatment of sleep disorders.

Tasimelteon is a pharmaceutical agent that acts as a selective dual melatonin receptor agonist. Its primary therapeutic application lies in the treatment of sleep disorders characterized by circadian rhythm disruption. By mimicking the effects of endogenous melatonin, Tasimelteon helps to reset and stabilize the body's internal sleep-wake cycle. This mechanism is particularly beneficial for patients suffering from conditions where the natural circadian rhythm is misaligned or disrupted.

One of the primary indications for Tasimelteon is Non-24-Hour Sleep-Wake Disorder (Non-24HSWD). This condition is particularly prevalent in individuals who are totally blind, as they lack the necessary light cues to synchronize their biological clock with the 24-hour day. This can lead to a progressively delayed sleep onset, resulting in insomnia at night and significant daytime sleepiness. Tasimelteon's ability to activate melatonin receptors in the brain aids in re-establishing a synchronized circadian rhythm, thereby improving sleep patterns. The role of tasimelteon in Non-24HSWD is well-established in clinical practice.

Additionally, Tasimelteon is indicated for managing nighttime sleep disturbances in patients diagnosed with Smith-Magenis Syndrome (SMS). SMS is a complex genetic disorder often associated with abnormal sleep patterns, including fragmented sleep and difficulty maintaining consolidated nighttime rest. Tasimelteon provides a pharmacological intervention to help normalize these sleep disturbances, contributing to improved sleep quality and overall patient well-being. The use of melatonin receptor agonists in managing complex sleep issues is a growing area of interest.

From a pharmaceutical supply perspective, NINGBO INNO PHARMCHEM CO.,LTD. ensures the availability of high-purity Tasimelteon to support both clinical use and ongoing research. Understanding the tasimelteon drugbank information and its various synonyms, such as Hetlioz and BMS-214778, is crucial for accurate procurement and research. Our role is to provide the necessary pharmaceutical chemical building blocks for advanced therapies.

In conclusion, Tasimelteon represents a targeted therapeutic option for specific circadian rhythm sleep disorders. Its mechanism of action as a melatonin receptor agonist makes it a valuable tool for medical professionals addressing conditions like Non-24HSWD and sleep disturbances in SMS. NINGBO INNO PHARMCHEM CO.,LTD. is dedicated to supporting the healthcare sector with essential pharmaceutical ingredients.